1-14 of 14
Shenmiao Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 6773.
https://doi.org/10.1182/blood-2024-206560
Published: 2024
Journal Articles

Acalabrutinib in Chinese Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 24-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yanqiu Han, Lindong Li, Yujie Wang, Xiaofeng Liu, Jianyong Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 6767.
https://doi.org/10.1182/blood-2024-193416
Published: 2024
Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang
Journal: Blood
Blood (2024) 144 (Supplement 1): 7819.
https://doi.org/10.1182/blood-2024-210572
Published: 2024
Journal Articles

A Matched Comparison of Pola-R-CHP Vs. R-CHOP for DLBCL with Extranodal Involvement

Shenmiao Yang, Rong Wei, Yang Liu, Xuelin Dou, Lei Wen, Jin Lu, Fengrong Wang, Xiaodong Mo, Xiaojun Huang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6478.
https://doi.org/10.1182/blood-2024-211660
Published: 2024
Journal Articles

Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yanqiu Han, Lindong Li, Anna Butturini, Yujie Wang, Xiaofeng Liu, Peiqiong Lai, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 6537.
https://doi.org/10.1182/blood-2023-173399
Published: 2023
Journal Articles

A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma

Fengrong Wang, Shenmiao Yang, Yu Wang, Jin Lu, Kaiyan Liu, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 10639–10640.
https://doi.org/10.1182/blood-2022-166839
Published: 2022
Journal Articles

Why Don't Asians Get Chronic Lymphocytic Leukaemia? It's in Their Genes

Shenmiao Yang, Dan Liu, Wenbing Liu, Xiaojun Huang, Qian-fei Wang, Robert Peter Gale
Journal: Blood
Blood (2022) 140 (Supplement 1): 12365–12366.
https://doi.org/10.1182/blood-2022-165042
Published: 2022
Journal Articles

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Caixia Li, Jia Wei, Keshu Zhou, Peng Liu, He Huang, Fei Li, Yujun Dong, Qingqing Cai, Shenmiao Yang, Xinyou Zhang, Hui Zhou, Lu Zhang, Zaixing Shi, Zhiyu Liang, Binghao Wu, Depei Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6717–6718.
https://doi.org/10.1182/blood-2022-171046
Published: 2022
Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Wei Xu, Yongping Song, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Jianfeng Zhou, Sujun Gao, Kaiyang Ding, Huilai Zhang, Zunmin Zhu, Shunqing Wang, Bing Xu, Jianda Hu, Ting Liu, Chunyan Ji, Zhongjun Xia, Yan Li, Xin Wang, Bin Zhang, Renbin Zhao, Jianyong Li
Journal: Blood
Blood (2021) 138 (Supplement 1): 2638.
https://doi.org/10.1182/blood-2021-146491
Published: 2021
Journal Articles

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Wei Xu, Shenmiao Yang, Constantine S. Tam, MBBS, MD, John F. Seymour, Keshu Zhou, MD PhD, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Lugui Qiu, MD, Mingyuan Sun, Tingyu Wang, Judith Trotman, FRACP, Ling Pan, MD PhD, Sujun Gao, Jianfeng Zhou, MD PhD, Daobin Zhou, MD PhD, Jun Zhu, Yuqin Song, MD PhD, Jianda Hu, MDPhD, Ru Feng, Haiwen Huang, Zhiyue Huang, Huafei Lu, Jianyong Li, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-136236
Published: 2020
Journal Articles

Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Wei Xu, MD PhD, Yongping Song, MD, Tingyu Wang, Shenmiao Yang, Lihong Liu, MD, Yu Hu, MD, Wei Zhang, Jianfeng Zhou, MD PhD, Sujun Gao, Kaiyang Ding, Huilai Zhang, MD PhD, Zunmin Zhu, MD, Shun-Qing Wang, Bing Xu, MD PhD, Jianda Hu, Ting Liu, MD PhD, Chunyan Ji, MD, Zhongjun Xia, MDPhD, Yan Li, PhDMD, Xin Wang, MDPhD, Huaqiang Zhu, MD, Renbin Zhao, PhD, Bin Zhang, PhD, Zhixin Xu, MD PhD, Jianyong Li, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-134531
Published: 2020
Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Wei Xu, MD PhD, Yongping Song, Zengjun Li, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Jianfeng Zhou, Sujun Gao, PhD, Kaiyang Ding, Huilai Zhang, MD, Zunmin Zhu, MD, Shunqing Wang, Bing Xu, Jianda Hu, PhD, Ting Liu, MD, Chunyan Ji, Zhongjun Xia, MD, Yan Li, PhDMD, Xin Wang, MD PhD, Zhixin Xu, Renbin Zhao, Bin Zhang, PhD, Alan Zhu, Jianyong Li, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4319.
https://doi.org/10.1182/blood-2019-123331
Published: 2019
Journal Articles

the Poorer-Risk AML, the Weaker Immunologic Surveillance? --Higher PD-L1 Expression on Non-APL AML Cells Is Associated with Poorer Risk Status According to Cytogenetics and Molecular Abnormailties

Shenmiao Yang, MD, Xiao Jun Huang, MD
Journal: Blood
Blood (2016) 128 (22): 1619.
https://doi.org/10.1182/blood.V128.22.1619.1619
Published: 2016
Journal Articles

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Shenmiao Yang, MD, Aijun Liu, MD, Yuping Zhong, MD, Xiaojun Huang, MDPhD, Wenming Chen, MD, Jin Lu
Journal: Blood
Blood (2015) 126 (23): 4247.
https://doi.org/10.1182/blood.V126.23.4247.4247
Published: 2015